Ir para o conteúdo principal
Grafa
Health
Sol-Gel reports lower revenue of $0.6 million
Image for illustrative purposes only. Not a real photo.

Sol-Gel reports lower revenue of $0.6 million

Share
  • Sol-Gel (NASDAQ:SLGL) reported Q2 2026 revenue of $0.6 million, compared with $17.3 million a year earlier.
  • The company reported a net loss of $3.7 million as prior-year revenue included a $16.7 million IP sale.
  • Sol-Gel said its Phase 3 SGT-610 trial remains on track for late November 2026 top-line data.

Sol-Gel (NASDAQ:SLGL) reported second quarter 2026 revenue of $0.6 million, down from $17.3 million a year earlier due mainly to a prior-year $16.7 million intellectual property sale to Mayne.

The results compared with Q2 2025, when the company recorded revenue from the IP transaction and reported net income, while the latest quarter reflected ongoing research and development activities.

“[Insert quote here],” said Sol-Gel [Designation] [Person’s Name].

Sol-Gel reported a Q2 2026 net loss of $3.7 million, or $1.13 per share, while research and development expenses declined to $3.7 million and general and administrative expenses decreased to $1.0 million.

Following the announcement the Sol-Gel share price was [up/down/unchanged] at $XX.

The company held $49.3 million in cash, cash equivalents, deposits and marketable securities as of June 30, 2026, and expects its available resources to fund operations into the first quarter of 2028.

Sol-Gel’s Phase 3 SGT-610 trial for Gorlin syndrome remains on schedule, with the last patient visit expected in September 2026 and top-line data expected in late November 2026, while additional studies are underway in basal cell carcinoma and related treatments.